Findings on Biosimilar Nonmedical Switching Costs Presented at European Congress of Rheumatology
June 19, 2018
Analysis Group Managing Principal Eric Q. Wu and Manager Min Yang were integral members of a research team conducting a systematic literature review on the costs associated with nonmedical switching from originator biologics to biosimilars. An abstract of the research was accepted for publication by the European League Against Rheumatism's 2018 Annual European Congress of Rheumatology (EULAR).
This literature review surfaced only three real-world studies that reported healthcare resource use associated with nonmedical switching. All three studies showed an increase in healthcare resource utilization after patients switched to a biosimilar for nonmedical reasons. The team recommends that a comprehensive evaluation of the economic consequences of switching should not be based solely on drug prices, but should also incorporate factors such as health care resource utilization.
To help advance a better understanding of the total economic impacts associated with nonmedical switching from originator biologics to biosimilars, Dr. Wu and Dr. Yang are preparing a full manuscript based on this research.